Charles Schwab
MLYS icon

Charles Schwab’s Mineralys Therapeutics MLYS Stock Holding History

Charles Schwab’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1M Buy
521,216
+77,318
+17% +$2.12M ﹤0.01% 1991
2026
Q1 		$12M Sell
443,898
-17,402
-4% -$510K ﹤0.01% 2014
2025
Q4 		$16.7M Buy
461,300
+52,113
+13% +$2.09M ﹤0.01% 1864
2025
Q3 		$15.5M Buy
409,187
+84,982
+26% +$1.84M ﹤0.01% 1885
2025
Q2 		$4.39M Buy
324,205
+54,030
+20% +$783K ﹤0.01% 2378
2025
Q1 		$4.29M Buy
270,175
+55,269
+26% +$636K ﹤0.01% 2331
2024
Q4 		$2.65M Buy
214,906
+1,307
+0.6% +$17.1K ﹤0.01% 2593
2024
Q3 		$2.59M Buy
213,599
+9,664
+5% +$117K ﹤0.01% 2629
2024
Q2 		$2.39M Buy
203,935
+83,073
+69% +$1.05M ﹤0.01% 2648
2024
Q1 		$1.56M Sell
120,862
-10
-0% -$123 ﹤0.01% 2665
2023
Q4 		$1.04M Buy
120,872
+14,466
+14% +$114K ﹤0.01% 2815
2023
Q3 		$1.01M Buy
106,406
+10,715
+11% +$140K ﹤0.01% 2795
2023
Q2 		$1.63M Buy
95,691
+6,731
+8% +$101K ﹤0.01% 2612
2023
Q1 		$1.39M Buy
+88,960
New +$1.5M ﹤0.01% 2622

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Charles Schwab's MLYS Position: Q2 2026 in Review

Charles Schwab increased its Mineralys Therapeutics (MLYS) stake by 17% in Q2 2026, buying an estimated $2.12M and bringing the position to 521,216 shares worth $14.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1991.

Charles Schwab first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. The position peaked at $16.7M in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Charles Schwab held 521,216 shares of Mineralys Therapeutics worth $14.1M as of Q2 2026.
  • Charles Schwab bought 77,318 Mineralys Therapeutics shares in Q2 2026, an estimated $2.12M.
  • Mineralys Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1991 holding.
  • Charles Schwab first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Charles Schwab's Mineralys Therapeutics position peaked at $16.7M in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.